Stock AnalizAcadia Healthcare Company, Inc. ACHC
Medical Specialities · data as of November 13, 2026
Acadia Healthcare Company, Inc. (ACHC) is a healthcare company listed in the US with a market value of about $3.5B. In the twelve months to September 30, 2026 it had revenue of $3.4B and net income of -$1.1B, a net margin of -33.1%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 56% below the current price.
Score: 0.4 / 5
Checks passed
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.3B | $3.2B | $2.9B | $2.6B | $2.3B | $2.1B | $2.0B | $1.9B | $2.8B | $2.8B |
| Net income | -$1.1B | -$1.1B | $256M | -$22M | $273M | $191M | -$672M | $109M | -$176M | $200M | $6M |
| Free cash flow | -$24M | -$440M | -$561M | $38M | $84M | $130M | $434M | $100M | $161M | $125M | $54M |
| EPS (diluted) | $-12.43 | $-12.16 | $2.78 | $-0.24 | $2.98 | $2.10 | $-7.59 | $1.24 | $-2.01 | $2.30 | $0.07 |
| Net margin | -33.1% | -33.3% | 8.1% | -0.7% | 10.5% | 8.2% | -32.2% | 5.4% | -9.2% | 7.0% | 0.2% |
| ROIC | — | -18.3% | 5.1% | -0.4% | 6.5% | 5.0% | 2.8% | 6.4% | 9.2% | 8.8% | 8.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $38.79, 3% above the current price; targets range from $19.00 to $46.00; the consensus rating is “Buy”; expected EPS is $1.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Acadia Healthcare Company stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 56% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Acadia Healthcare Company pay a dividend?
Not currently.
Is Acadia Healthcare Company a good stock to buy?
We do not give buy or sell advice. Acadia Healthcare Company scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.